Valuation: Lupin Limited

Market Cap 1,132B 11.89B 10.39B 9.55B 8.9B 16.89B 17.14B 115B 44.58B 556B 44.63B 43.67B 1,918B P/E 2026
19.9x
P/E 2027 * 24.6x
Enterprise Value 1,119B 11.75B 10.27B 9.44B 8.8B 16.69B 16.94B 113B 44.06B 550B 44.11B 43.16B 1,895B EV / Sales 2026
3.69x
EV / Sales 2027 * 3.68x
Free-Float
52.97%
Yield 2026
0.78%
Yield 2027 * 0.52%
1 day+0.72%
1 week+3.60%
Current month+3.05%
1 month+10.72%
3 months+9.49%
6 months+15.89%
Current year+18.09%
1 week 2,382.55
Extreme 2382.55
2,504.95
1 month 2,230.25
Extreme 2230.25
2,504.95
Current year 2,072.95
Extreme 2072.95
2,504.95
1 year 1,838.65
Extreme 1838.65
2,504.95
3 years 889.85
Extreme 889.85
2,504.95
5 years 583.05
Extreme 583.05
2,504.95
10 years 505
Extreme 505
2,504.95
Manager TitleAgeSince
Chief Executive Officer 58 2013-08-31
Director of Finance/CFO 61 2007-08-12
Compliance Officer - 2024-08-31
Director TitleAgeSince
Director/Board Member 52 2008-10-07
Director/Board Member 58 1996-12-31
Chairman 82 2017-08-10
Change 5-day change 1-year change 3-year change Capi.($)
+0.72%+3.60%+26.13%+175.53% 11.89B
+1.86%+0.48%+55.50%+160.66% 1,082B
+3.57%+3.29%+68.60%+61.56% 633B
+3.99%+3.05%+37.93%+89.70% 461B
-1.41%+1.37%+31.00%+23.05% 338B
-0.68%+0.52%+40.65%+39.16% 299B
-0.31%+1.01%+30.60%+45.41% 291B
-0.29%+3.56%-26.09%-39.73% 222B
+3.55%+4.41%+25.45%+65.64% 202B
+4.21%+2.65%+17.47%+69.95% 163B
Average +1.52%+4.58%+30.72%+69.09% 370.43B
Weighted average by Cap. +1.81%+5.43%+41.87%+82.33%

Financials

2026 2027 *
Net sales 272B 2.85B 2.49B 2.29B 2.14B 4.05B 4.11B 27.52B 10.7B 134B 10.71B 10.48B 460B 296B 3.11B 2.72B 2.5B 2.33B 4.42B 4.49B 30.03B 11.67B 146B 11.69B 11.44B 502B
Net income 49.02B 515M 450M 414M 386M 731M 742M 4.97B 1.93B 24.1B 1.93B 1.89B 83.03B 45.98B 483M 422M 388M 362M 686M 696M 4.66B 1.81B 22.6B 1.81B 1.77B 77.89B
Net Debt -13.22B -139M -121M -112M -104M -197M -200M -1.34B -521M -6.5B -521M -510M -22.4B -42.53B -447M -391M -359M -335M -635M -644M -4.31B -1.67B -20.91B -1.68B -1.64B -72.05B
Logo Lupin Limited
Lupin Limited is a leading Indian pharmaceutical group. Its products are used to treat tuberculosis, diabetes, asthma, cardiovascular diseases, infections, etc. The group's activity is organized around 2 areas: - design and production of generic and brand-name formulations; - production of active pharmaceutical ingredients. At the end of March 2022, the group had 15 production sites India (12), the United States, Mexico and Brazil. Net sales break down geographically as follows: India (39.4%), the United States (34.1%) and other (26.5%).
Employees
24,006
Date Price Change Volume
26-07-06 2,493.90 +0.72% 40,299
26-07-03 ₹2,476.10 +3.23% 26,074
26-07-02 ₹2,398.70 +0.09% 17,171
26-07-01 ₹2,396.50 -0.98% 31,634
26-06-30 ₹2,420.15 +0.53% 36,595
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
37
Last Close Price
2,476.10INR
Average target price
2,466.51INR
Spread / Average Target
-0.39%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LUPIN Stock